These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24152955)

  • 41. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
    Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
    Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
    Kawada N; Uehara H; Katayama K; Nakamura S; Takahashi H; Ohigashi H; Ishikawa O; Nagata S; Tomita Y
    J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):717-22. PubMed ID: 22426593
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
    D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V
    Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
    Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
    Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?
    Mohelnikova-Duchonova B; Melichar B
    Pancreatology; 2013; 13(6):558-63. PubMed ID: 24280569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells.
    Murata A; Nakata B; Komoto M; Hirata K; Kimura K; Amano R; Hirakawa K
    Hepatogastroenterology; 2013 Sep; 60(126):1484-7. PubMed ID: 23933942
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
    Xie H; Jiang W; Jiang J; Wang Y; Kim R; Liu X; Liu X
    Cancer; 2013 Jan; 119(1):173-81. PubMed ID: 22736490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
    Poplin E; Wasan H; Rolfe L; Raponi M; Ikdahl T; Bondarenko I; Davidenko I; Bondar V; Garin A; Boeck S; Ormanns S; Heinemann V; Bassi C; Evans TR; Andersson R; Hahn H; Picozzi V; Dicker A; Mann E; Voong C; Kaur P; Isaacson J; Allen A
    J Clin Oncol; 2013 Dec; 31(35):4453-61. PubMed ID: 24220555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.
    Brandi G; Deserti M; Vasuri F; Farioli A; Degiovanni A; Palloni A; Frega G; Barbera MA; de Lorenzo S; Garajova I; Di Marco M; Pinna AD; Cescon M; Cucchetti A; Ercolani G; D'Errico-Grigioni A; Pantaleo MA; Biasco G; Tavolari S;
    Oncologist; 2016 May; 21(5):600-7. PubMed ID: 27032872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
    Vincenzi B; Stacchiotti S; Collini P; Pantano F; Rabitti C; Perrone G; Iuliani M; Baldi A; Badalamenti G; Sanfilippo R; Santini D; Muda AO; Gronchi A; Casali P; Dei Tos AP; Tonini G
    Br J Cancer; 2017 Jul; 117(3):340-346. PubMed ID: 28641307
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics in pancreatic cancer.
    Tourkantonis IS; Peponi E; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):335-9. PubMed ID: 25076337
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
    Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
    J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
    Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
    Ormanns S; Heinemann V; Raponi M; Isaacson J; Laubender RP; Haas M; Kruger S; Kleespies A; Mann E; Bartosiewicz M; Kirchner T; Boeck S
    Eur J Cancer; 2014 Jul; 50(11):1891-9. PubMed ID: 24857044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
    Kasuya K; Tsuchida A; Nagakawa Y; Suzuki Y; Suzuki M; Aoki T; Abe Y; Shimazu M; Itoi T; Sofuni A
    Hepatogastroenterology; 2012; 59(117):1609-13. PubMed ID: 22155850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
    Li D; Pant S; Ryan DP; Laheru D; Bahary N; Dragovich T; Hosein PJ; Rolfe L; Saif MW; LaValle J; Yu KH; Lowery MA; Allen A; O'Reilly EM
    Pancreatology; 2014; 14(5):398-402. PubMed ID: 25278310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
    Attia F; Fathy S; Anani M; Hassan A; Attia F; Ibrahim G; Elazab M
    J Clin Lab Anal; 2020 Nov; 34(11):e23457. PubMed ID: 32671914
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
    Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.
    Farrell JJ; Moughan J; Wong JL; Regine WF; Schaefer P; Benson AB; Macdonald JS; Liu X; Yen Y; Lai R; Zheng Z; Bepler G; Guha C; Elsaleh H
    Pancreas; 2016 Nov; 45(10):1485-1493. PubMed ID: 27748721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.